Physician profile
Richard M Ingram
NPI 1669416350
$1,858.92
in general payments reported to CMS, 2019-2025
23 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $834 · 2021: $141 · 2022: $128 · 2023: $211 · 2024: $138 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.59 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $800.00 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $204.56 | 2019-2023 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $149.47 | 2022-2024 | Calquence |
| Pharmacyclics LLC, An Abbvie Company | $105.78 | 2021-2023 | Imbruvica |
| Avyxa Pharma, LLC | $61.28 | 2025 | |
| Pfizer INC. | $59.13 | 2019-2025 | |
| Genentech USA, INC. | $53.45 | 2025 | |
| Eisai INC. | $49.03 | 2021-2023 | |
| Array Biopharma INC | $48.44 | 2022-2025 | Braftovi, Lorbrena, Mektovi |
| Merck Sharp & Dohme LLC | $42.25 | 2024-2025 | Keytruda |
| Celgene Corporation | $37.56 | 2022 | |
| Abbvie INC. | $31.36 | 2024 | |
| Novartis Pharmaceuticals Corporation | $29.18 | 2024 | |
| Medtronic, INC. | $27.05 | 2021-2025 | Synchromedii |
| Asd Specialty Healthcare, LLC | $25.87 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iovance Biotherapeutics, INC. | $20.36 | 2024 | Amtagvi |
| Beigene USA, INC. | $19.73 | 2022 | |
| Amneal Pharmaceuticals LLC | $19.04 | 2025 | Alymsys |
| Cti Biopharma Corp. | $17.32 | 2023 | Vonjo |
| Sumitomo Pharma America, INC. | $17.29 | 2023 | Orgovyx |
| Kyowa Kirin, INC. | $17.22 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ingram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.